PTEN and prostate carcinoma: To test whether SART is effective in this prostate cancer model, Pten;Trp53pc−/− male mice were randomized to 5 fractions of 0, 7.5, or 9 Gy (Fig. 6d, Study 1) at 5 months of age, a time point when tumors were clinically apparent.